What is the current Price Target for the Edgewise Therapeutics Inc stock?

The average Edgewise Therapeutics Inc target price is $41.22. This is 203.55% higher than the current stock price. The highest price target is 282.92%, the lowest is 3.09%. 9 Analysts have issued a price target Edgewise Therapeutics Inc 2026 .

How high will the Edgewise Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Edgewise Therapeutics Inc stock will rise. The performance of stocks, including the Edgewise Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Edgewise Therapeutics Inc stock today?

The performance of Edgewise Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Edgewise Therapeutics Inc stock fall?

The decline in Edgewise Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Edgewise Therapeutics Inc Forecast, price target & analysts

$12.35

9.06% today

Nasdaq, Apr 04, 05:51 pm CET

ISIN

US28036F1057

Symbol

EWTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Edgewise Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Edgewise Therapeutics Inc Classifications & Recommendation:

Buy

78%

Hold

22%

Edgewise Therapeutics Inc Price Target

Target Price	$41.22
Price	$13.58
Potential	203.55% register free of charge
Number of Estimates	9

	9 Analysts have issued a price target Edgewise Therapeutics Inc 2026 . The average Edgewise Therapeutics Inc target price is $41.22. This is 203.55% register free of charge higher than the current stock price. The highest price target is $52.00 282.92% register free of charge , the lowest is $14.00 3.09% register free of charge .
	A rating was issued by 9 analysts: 7 Analysts recommend Edgewise Therapeutics Inc to buy, 2 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Edgewise Therapeutics Inc stock has an average upside potential 2026 of 203.55% register free of charge . Most analysts recommend the Edgewise Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-1.45	-1.83
	7.64%	26.21%
P/E		negative

4 Analysts have issued a Edgewise Therapeutics Inc forecast for earnings per share. The average Edgewise Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-1.45	7.64%
2025	$-1.83 26.21% Unlock
2026	$-1.99 8.74% Unlock
2027	$-2.08 4.52% Unlock
2028	$-0.27 87.02% Unlock
2029	$2.60 1,062.96% Unlock

Current	-9.40	19.10%
2025	-7.42 21.06% Unlock
2026	-6.82 8.09% Unlock
2027	-6.51 4.55% Unlock
2028	-51.25 687.25% Unlock
2029	5.23 110.20% Unlock

Edgewise Therapeutics Inc...

Current Edgewise Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
RBC Capital	Locked ➜ Locked	Locked	Apr 03 2025
Scotiabank	Locked ➜ Locked	Locked	Apr 03 2025
Piper Sandler	Locked ➜ Locked	Locked	Apr 02 2025
Scotiabank	Locked ➜ Locked	Locked	Mar 07 2025
RBC Capital	Locked ➜ Locked	Locked	Mar 04 2025
Stifel	Locked ➜ Locked	Locked	Jan 22 2025
Evercore ISI Group	Locked ➜ Locked	Locked	Dec 17 2024

Analyst Rating	Date
Locked RBC Capital: Locked ➜ Locked	Apr 03 2025
Locked Scotiabank: Locked ➜ Locked	Apr 03 2025
Locked Piper Sandler: Locked ➜ Locked	Apr 02 2025
Locked Scotiabank: Locked ➜ Locked	Mar 07 2025
Locked RBC Capital: Locked ➜ Locked	Mar 04 2025
Locked Stifel: Locked ➜ Locked	Jan 22 2025
Locked Evercore ISI Group: Locked ➜ Locked	Dec 17 2024

Discover more stocks with a high price target

Novo Nordisk 83.92%

Coinbase Global, Inc. 83.53%

BioNTech SE - ADR 50.09%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now